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Introduction
National and international point-prevalence studies show that 
64%–71% of all patients in intensive care units (ICUs) receive 
antibiotics (1, 2) and up to 10%–51% suffer from hospital-acquired 
infections (HAIs) (1–3). Recent estimates indicate that in Europe 
alone, 2.6 million cases of HAI occur each year, of which hospital-
acquired pneumonia (HAP) accounts for the highest disease bur-
den and number of deaths (4). HAP dramatically increases both 
the length of hospital stay and the healthcare costs, and is associ-
ated with an attributable mortality of up to 13% (5).
Pseudomonas aeruginosa represents an important opportu-
nistic pathogen in critically ill patients and is a leading cause of 
HAP (6). The bacterium is intrinsically resistant to many antibi-
otics and rapidly acquires additional drug resistance–conferring 
genetic information (7). Rates of carbapenem resistance among 
P. aeruginosa isolates, for example, range from 10%–50% in 
numerous countries (8), demanding novel strategies to prevent 
and treat infections with P. aeruginosa.
Preceding antimicrobial therapy is a major independent risk fac-
tor for lung infections with P. aeruginosa (9–12). International guide-
lines therefore specifically recommend the use of P. aeruginosa– 
active antibiotics for empirical treatment of HAP in patients with 
prior antibiotic use (11, 13, 14). However, the mechanism underly-
ing the enhanced P. aeruginosa infection susceptibility of patients 
receiving antimicrobial treatment is incompletely understood.
The microbiota mediates direct and indirect colonization 
resistance by outcompeting drug-resistant obligate or opportu-
nistic pathogens and maintaining the local production of antibac-
terial peptides (15, 16). Moreover, recent studies indicate a ben-
eficial influence of the microbiota on systemic and pulmonary 
immune responses during bacterial and viral infections. Accord-
ingly, the microbiota calibrates the immune system by adjusting 
the release of antiinflammatory IL-10 (17), releasing short-chain 
fatty acids to stimulate infection resolution via the G protein–
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P. aeruginosa–binding IgA were almost significantly decreased in the 
BALF of antibiotic-treated animals as compared with samples from 
control mice (Figure 2H). In order to examine whether impaired 
IgA production is indeed responsible for the enhanced susceptibil-
ity of microbiota-depleted animals toward acute P. aeruginosa lung 
infection, we compared bacterial clearance in WT and IgA-deficient 
mice that either received antibiotics or were left untreated. We 
observed that both microbiota-depleted WT and conventionally 
colonized IgA–/– mice harbored higher bacterial loads in the lungs 
and blood as compared with control animals (Figure 2I). Of note, 
microbiota depletion did not further increase the bacterial burden 
in lungs of IgA-deficient animals. However, a slight effect of anti-
biotic treatment of IgA–/– animals suggests a minor contribution of 
an IgA-independent mechanism of the microbiota to restrict bacte-
rial dissemination (Figure 2J). Taken together, these data reveal that 
IgA contributes to the early antibacterial defense during P. aerugi-
nosa–induced pneumonia, and that antibiotic-mediated microbiota 
depletion following antibiotic administration impairs the resistance 
of mice by lowering IgA levels.
IgA production in the lung is dependent on TLR and a proliferation-
inducing ligand (APRIL). Next, we aimed to unravel the mechanism 
that drives IgA production in the lung in the presence of the micro-
biota. Innate immune stimulation mediated, for example, through 
the family of TLRs provides the costimulus required for an effi-
cient adaptive immune response (27). We therefore analyzed mice 
devoid of TLR activities due to lack of expression of TLR2, TLR4, 
and TLR5 as well as the endosomal TLR chaperone UNC93B1 (3d/
Tlr2/4/5–/–). In 3d/Tlr2/4/5–/– mice, production of IgA (Figure 3A), 
frequency of total IgA+ cells (Figure 3, B and C) and IgA+ plasma cells 
(Figure 3, B and D), and levels of P. aeruginosa–binding IgA (Figure 
3E) were strongly reduced. In contrast, IgA levels were not affected 
by lack of TLR2 and TLR4 alone (Supplemental Figure 3, A and B). 
Accordingly, oral or intranasal application of the TLR4 agonist LPS 
did not affect IgA levels in antibiotic-treated animals (Supplemental 
Figure 3, C–F), although intranasal pretreatment with LPS increased 
(apparently IgA-independent) antibacterial defense in the lung 
against P. aeruginosa (Supplemental Figure 3, G–J). Moreover, IgA 
production was also reduced in T cell–deficient animals (Figure 3F).
Production of intestinal IgA has been shown to depend on the 
TNF family cytokine APRIL and B cell–activating factor (BAFF) 
(28–30). Accordingly, the lungs of antibiotic-treated and 3d/
Tlr2/4/5–/– animals contained lower levels of APRIL, and by trend 
of BAFF, as compared with lungs of respective control groups 
(Figure 3, G–J). Moreover, constitutive IgA production was vir-
tually absent in mice lacking expression of the APRIL and BAFF 
receptors transmembrane activator and CAML interactor (TACI) 
and B cell maturation antigen (BCMA) (hereafter referred to as 
Taci/Bcma–/– mice) (Figure 3K). Together, our data indicate the 
requirement of microbiota-dependent activation of TLRs (prob-
ably involving members other than TLR2/4) for APRIL expression 
(and possibly BAFF expression) and IgA production in the lung.
Clinical antimicrobial therapies lower IgA levels in mice and 
human patients. We next asked whether clinically relevant antimi-
crobial drugs exhibited a similar effect on IgA production. Indeed, 
we observed reduced levels of IgA (but not of IgM and IgG) in mice 
that were treated for 4 weeks with amoxicillin and clavulanate as 
compared with control mice (Figure 4, A and B, and our unpub-
coupled receptor 43 (18), enhancing the antibacterial activity 
of neutrophils via NOD1 (19), priming inflammasome activities 
(20), and controlling responsiveness of mononuclear phagocytes 
to produce type I IFNs and other inflammatory cytokines (21, 
22). Antimicrobial therapies cause dramatic and long-lasting col-
lateral damage to the bacterial populations forming the patient’s 
microbiota (23, 24). Whether an impairment of aforementioned 
or other microbiota-dependent mechanisms explains the high 
susceptibility of individuals receiving antibiotics toward P. aeru-
ginosa infection is currently unknown.
Here we examine the effect of preceding antimicrobial thera-
py on acute lung infection and identify a novel mechanism under-
lying the high risk of individuals receiving antibiotics to develop 
P. aeruginosa pneumonia.
Results
Antibiotic-mediated microbiota depletion enhances susceptibility 
to P. aeruginosa–induced pneumonia. In order to assess the effect 
of the microbiota on P. aeruginosa–induced pneumonia, we first 
examined mice that received a cocktail of antibiotics to deplete 
the microbiota, as previously described (25). As expected, the 
antimicrobial treatment virtually depleted the respiratory and 
intestinal microbiota (Supplemental Figure 1, A–C; supplemental 
material available online with this article; https://doi.org/10.1172/
JCI97065DS1). Mice were intranasally infected with P. aeruginosa 
4 to 5 days after ending antibiotic treatment. Microbiota-depleted 
mice showed an early defect in bacterial clearance in the lung (Fig-
ure 1, A and B), enhanced dissemination into the blood (Figure 1C), 
and reduced survival (Figure 1D) as compared with conventionally 
colonized mice. Similarly, animals born germ-free (GF) exhibited 
dramatically enhanced bacterial loads in the lung and blood com-
pared with conventionally colonized mice (Supplemental Figure 
2, A and B). The early inflammatory response, however, did not 
seem to be impaired by microbiota depletion. The production of 
several inflammatory mediators and recruitment of neutrophils 
were not inhibited by microbiota depletion, but rather were slight-
ly enhanced, probably due to enhanced proliferation of P. aerugi-
nosa (Figure 1, E–O). Microbiota depletion also did not generally 
increase vascular permeability, as detected by leakage of Evans 
blue dye (Figure 1P). These results imply an impact of microbiota 
depletion on a defense mechanism beyond the mechanisms ana-
lyzed as central for early P. aeruginosa resistance in the lung.
Microbiota-dependent IgA production contributes to control of 
P. aeruginosa infection. Considering humoral immune dysfunc-
tion as a potential mechanism underlying the high susceptibility 
of microbiota-depleted animals to P. aeruginosa infection (26), we 
next analyzed production of immunoglobulins. While IgM and 
IgG antibody titers were unaltered, we observed strongly reduced 
IgA levels in the lung and blood of antibiotic-treated animals as 
compared with control counterparts (Figure 2, A–D). According-
ly, microbiota depletion lowered the frequency of total IgA+ cells 
(probably consisting of IgA+ plasma cells, IgA+ plasmablasts, B 
cells, and cells expressing the polymeric immunoglobulin recep-
tor carrying IgA; Figure 2, E and F) and IgA+ plasma cells (Figure 
2, E and G) in the lung. Next, we coated ELISA plates with P. aeru-
ginosa, incubated with bronchoalveolar lavage fluid (BALF) sam-
ples, quantified the bacteria-binding IgA, and found that levels of 
The Journal of Clinical Investigation   R E S E A R C H  A R T I C L E
3 5 3 7jci.org   Volume 128   Number 8   August 2018
Figure 1. Antibiotic-mediated microbiota depletion impairs antibacterial defense against P. aeruginosa. (A–D) Conventionally colonized mice (Conv) 
and mice that were treated with an antibiotic cocktail for 6–8 weeks (ABx) were infected with P. aeruginosa. (A) Bacterial loads in BALF (n = 9), (B) lung 
tissue (n = 11 for Conv mice; n = 9 for ABx mice), and (C) blood (n = 11 for Conv mice; n = 9 for ABx mice) were counted at the indicated time points, or (D) 
survival was monitored (n = 11 for Conv mice; n = 12 for ABx mice). (E–M) Mice were intranasally infected with P. aeruginosa or treated with PBS for  
6 hours. Production of inflammatory mediators was measured by ELISA (n = 10 for uninfected Conv and ABx mice; n = 10 for infected Conv mice; n = 11 for 
infected ABx mice) and qRT-PCR (n = 8 for uninfected Conv and ABx mice; n = 10 for infected Conv mice; n = 9 for infected ABx mice). (N and O) Alveolar 
macrophages (n = 9 for uninfected Conv and ABx mice; n = 9 for infected Conv mice; n = 7 for infected ABx mice) and neutrophils (n = 9 for uninfected 
Conv and ABx mice; n = 9 for infected Conv mice; n = 8 for infected ABx mice) were counted by FACS analysis after staining of BALF samples. (P) Lung 
vascular permeability of control and microbiota-depleted animals was measured by Evans blue dye leakage in the lungs (n = 8 for Conv; n = 8 for ABx 
mice). Mann-Whitney U tests were applied to the data set, except for the survival curve (D), which was submitted to log-rank test. Values are mean ± 
SD. *P < 0.05, **P < 0.01, ***P < 0.005.
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antibiotic-treated patients (Figure 4H). These results indicate that 
clinically relevant antimicrobial therapies reduce pulmonary IgA 
production. They suggest that the antibiotic-associated secondary 
IgA deficiency contributes to a high susceptibility of ICU patients 
toward P. aeruginosa (and possibly other bacterial) infections.
Local application of IgA increases resistance of antibiotic-treated 
mice. Finally, we tested whether local (i.e., pulmonary) applica-
tion of IgA rescues the antibacterial defense in antibiotic-treated 
mice. First, polyclonal IgA was affinity purified from supernatants 
of ex vivo murine intestinal tissue cultures and found to bind to P. 
aeruginosa (our unpublished observation). Mouse polyclonal IgA 
of the source described above was further intranasally applied to 
antibiotic-pretreated animals 30 minutes prior to P. aeruginosa 
infection. Importantly, IgA-treated animals harbored fewer bacte-
lished observations). Next, we examined the effect of antimicro-
bial therapies on pulmonary IgA production in human patients. 
We compared BALF samples from ICU patients who were either 
treated with antibiotics at the time of sampling (at least one broad-
spectrum antibiotic for at least 2 weeks; for details refer to Table 
1) or who did not receive antibiotic therapy for at least 3 months 
before sampling. Antibiotic-treated patients showed unaltered IgM 
and IgG levels (Figure 4, C and D), but significantly lower levels of 
APRIL, BAFF, and total IgA in their BALFs as compared with indi-
viduals who did not receive antimicrobial therapy (Figure 4, E–G). 
According to the results of a univariate analysis, APRIL and BAFF 
levels affected IgA BALF levels in antibiotic-treated patients trend-
wise, since significance was not reached (P = 0.066). Moreover, 
levels of P. aeruginosa–binding IgA were reduced in the lungs of 
Figure 2. Microbiota depletion impairs antibacterial defense in the lung by decreasing pulmonary IgA production. (A–D) Total levels of (A) IgM (n = 8 for 
Conv; n = 5 for ABx mice), (B) IgG (n = 5 for Conv; n = 4 for ABx mice), and (C) IgA (n = 14 for Conv; n = 14 for ABx mice) in the BALF or (D) in plasma (n = 9 
for Conv; n = 7 for ABx mice) were measured. (E) Lung IgA+ plasma cells were identified by FACS as IgAhi (E, left) and B220lo CD138hi cells (E, right). (F) Total 
lung IgA+ cells and (G) IgA+ plasma cells were quantified by FACS (n = 10 for Conv and ABx mice). (H) Levels of P. aeruginosa–binding IgA were quantified by 
coating P. aeruginosa to ELISA plates and measuring bound IgA (n = 7 for Conv and ABx mice). (I, J) WT and IgA–/– mice were pretreated or not with antibi-
otics, and afterwards infected with 1 × 105 CFU per mouse P. aeruginosa. Bacterial loads in the (I) lungs and (J) blood were measured at 24 hours after infec-
tion (n = 24 for Conv WT; n = 28 for Conv IgA–/–; n = 9 for WT ABx; n = 12 for IgA–/– ABx mice). Mann-Whitney U tests were applied to the data set. Values are 
mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.005.
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ly reduced Pseudomonas dissemination into blood, as compared 
with PBS or nonbinding IgA (pool of 2 hybridoma preparations) 
(Figure 5, F and G). Collectively, these results indicate a substan-
tial capacity of pretreatment with IgA to improve the antibacterial 
host defense and thus enhance the resistance of antibiotic-treated 
mice against P. aeruginosa.
Discussion
Antimicrobial therapy constitutes a major risk factor for subse-
quent infection with P. aeruginosa and other antibiotic-resistant 
opportunistic pathogens (9–12). Our present study revealed that 
antibiotic-mediated inhibition of a microbiota-, TLR-, and APRIL-
dependent pulmonary production of (probably cross-reactive) 
ria in their lungs and blood as compared with control mice (Figure 
5, A and B). Accordingly, pretreatment of mice with a single dose 
of IgA reduced the infection-induced body temperature decrease 
(Figure 5C) and significantly prolonged the survival upon infec-
tion (Figure 5D). Next, we analyzed whether a P. aeruginosa–bind-
ing capacity of the administered IgA was required for its antibacte-
rial effect in microbiota-depleted animals. IgA preparations from 
various IgA hybridomas were tested for their capacity to bind to 
P. aeruginosa, grouped and pooled into high P. aeruginosa binders, 
intermediate P. aeruginosa binders, and non–P. aeruginosa binders 
(Figure 5E). Intranasal application of high P. aeruginosa–binding 
IgA (pool of 5 hybridoma preparations) 30 minutes prior to infec-
tion lowered the bacterial load in the lung by trend and significant-
Figure 3. IgA production is dependent on microbiota, TLRs, APRIL, and TACI/BCMA. (A) IgA levels in BALF (n = 10 for WT; n = 7 for 3d/Tlr2/4/5–/– mice) 
and (B–D) total IgA+ cells and IgA+ plasma cells in whole lungs of WT and 3d/Tlr2/4/5–/– (comprehensive and specific lack of TLR function) mice were 
examined (n = 10 for each group). (E) Levels of P. aeruginosa–binding IgA were examined in BALFs of WT and 3d/Tlr2/4/5–/– mice (n = 10 for WT; n = 7 for 
3d/Tlr2/4/5–/–). (F) IgA levels were measured in BALF of WT and Tcrbd–/– animals (n = 7 for WT; n = 10 for Tcrbd–/– mice). (G–J) Levels of APRIL and BAFF 
were measured in lung homogenate supernatants of animals as indicated (n = 10 for Conv mice; n = 5 for ABx mice; n = 10 for WT mice; n = 10 for 3d/
Tlr2/4/5–/– mice). (K) IgA levels were assessed in BALFs of WT and Taci/Bcma–/– animals (n = 8 for WT; n = 9 for Taci/Bcma–/–). Mann-Whitney U tests were 
applied to the data set. Values are mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.005, ****P < 0.001.
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IgA enhances the susceptibility of mice toward P. aeruginosa lung 
infection. Likewise, we found reduced IgA levels in ICU patients 
treated with antibiotics. This suggests that antibiotic-associated 
secondary IgA deficiency is relevant in humans and might con-
tribute to the high susceptibility of ICU patients toward infections 
with P. aeruginosa and possibly other bacteria. Finally, we demon-
strate that local application of IgA partially restored the antibac-
terial defense against P. aeruginosa in antibiotic-pretreated mice, 
and that the capacity to bind Pseudomonas is required for the pro-
tective effect of IgA. We therefore hypothesize that ICU patients 
on broad-spectrum antimicrobial therapy might benefit from 
prophylactic and/or therapeutic pulmonary IgA administration or 
other novel strategies to enhance local IgA levels.
Primary IgA deficiency is the most common genetic immuno-
deficiency, with a prevalence of approximately 1:600 in the West-
ern population (31). Recurrent pulmonary infections constitute the 
most prevalent comorbidity in IgA-deficient patients. However, 
many others remain asymptomatic, which could be explained by a 
compensatory increase in IgM production in individuals with pri-
mary IgA deficiency (32). Moreover, P. aeruginosa is poorly patho-
genic in (otherwise) healthy individuals, and most persons outside 
the hospital are not colonized with this bacterium. This potentially 
explains why individuals with primary IgA deficiency are typically 
not at risk for P. aeruginosa–induced pneumonia.
On the contrary, hospitalized patients are frequently colo-
nized with P. aeruginosa in the upper respiratory tract, which is 
the first step for subsequent lower respiratory tract infection (33). 
Our results suggest that the acquisition of antibiotic-dependent 
IgA deficiency (possibly in addition to the attenuation of other 
antibacterial immune pathways) in colonized patients allows aspi-
rated bacteria to replicate and disseminate to cause pneumonia. 
This assumption is supported by a small prospective study that 
found an association between low bronchial IgA levels and onset 
of nosocomial pneumonia in ventilated ICU patients (34).
Several clinical trials indicated that the administration of pro-
biotics to mechanically ventilated critically ill patients substan-
tially decreases the incidence of ventilator-associated pneumonia 
(35, 36). Although IgA levels have, to our best knowledge, not been 
examined in these studies, the protective probiotic effect might 
be at least partially mediated by rescue of pulmonary IgA produc-
tion. This assumption is supported by recent demonstration that 
oral application of bacterial extracts has the capability to enhance 
pulmonary IgA levels in mice (37).
It is well-established that the microbiota is critical for regu-
lating intestinal IgA production, as IgA-secreting cells and IgA 
production are almost absent in the intestinal tract of GF mice 
(38). Microbial signals are known to activate TLRs on intestinal 
DCs and epithelial cells to induce production of APRIL and BAFF, 
which in turn promote IgA production by plasma cells (29, 30, 39, 
40). Moreover, microbiota-derived short-chain fatty acids have 
recently been demonstrated to positively regulate IgA produc-
tion (41, 42). Production of high-affinity and antigen-specific IgA 
in Peyer’s patches and mesentery lymph nodes has further been 
shown to be T cell dependent (43), whereas low-affinity polyre-
active IgA responses were mainly induced in isolated lymphoid 
follicles and subepithelial B cells in a T cell–independent man-
ner (44). Both types of IgA regulate the composition of intestinal 
microbiota by coating many of its bacterial components to main-
tain intestinal homeostasis (45, 46). In addition, IgA has long been 
known to mediate neutralizing of invasive intestinal pathogens by 
various mechanisms (47, 48).
Considerably less is known about the regulation of IgA pro-
duction in the respiratory tract. A recent study demonstrated that 
the microbiota regulates the ability of specific lung DC subtypes 
Figure 4. Production of IgA is impaired by antimicrobial therapy in mice and ICU patients. (A and B) WT mice were treated with amoxicillin and clavu-
lanate (AmoxClav) for 4 weeks and IgA levels in the BALF (A) and plasma (B) were examined (n = 14 for mice without AmoxClav; n = 16 or 15 for mice with 
AmoxClav). (C–H) Levels of IgM, IgG, APRIL, BAFF, total IgA, and P. aeruginosa–binding IgA were measured by ELISA from human BALF samples of ICU 
patients with or without antimicrobial therapy (n = 10 for patients without ABx; n = 10 for patients with ABx). Mann-Whitney U tests were applied to the 
data set. Values are mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.005.
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to stimulate IgA class switch reaction and to induce gut homing 
molecules in B cells ex vivo (49). This was shown to depend on 
MyD88/TRIF-mediated TGF-β production as well as on retinoic 
acid, respectively. Moreover, this recent report revealed that the 
lung DC–dependent mechanism is critical for IgA-dependent gas-
trointestinal immune responses following intranasal immuniza-
tion (49). Our study provides important new insight by showing 
that microbiota-dependent IgA production is required for antibac-
terial immunity during acute bacterial pneumonia. Moreover, we 
indicate that this mechanism is attenuated by antimicrobial thera-
pies, and that the antibiotic-associated susceptibility to bacterial 
pneumonia can be reduced by local application of IgA.
Our data clearly show that attenuation of IgA production is 
causally linked to the enhanced susceptibility of antibiotic-treated 
animals to P. aeruginosa, and that application of IgA just 30 min-
utes before infection is sufficient to improve antibacterial defense. 
There are limitations to our study, how-
ever. First, our data do not exclude the 
possibility that regulation of additional 
antimicrobial pathways known to depend 
on microbiota signals (17, 19, 20, 50) 
might also play a role. Second, although 
our mouse experiments indicate a causal 
relationship among antibiotic-mediated 
microbiota depletion, attenuation of IgA 
production, and enhanced susceptibil-
ity to P. aeruginosa infection, the human 
data only show a correlation between 
antimicrobial therapy and low IgA lev-
els. Prospective studies examining the 
impact of antibiotics on pulmonary IgA 
production and incidence of HAP are 
therefore required before interventional 
studies to increase IgA levels in high-risk 
ICU patients might be considered. Future 
studies are also necessary to define 
the specificity of the respiratory and/
or intestinal microbiota being involved 
and how different classes of antibiot-
ics and respective delivery routes (e.g., 
oral, inhaled, or parenteral) impact IgA-
dependent immunity.
In summary, we here show that admin-
istration of broad-spectrum antibiotic 
inhibits microbiota-dependent IgA pro-
duction in the lung and increases suscep-
tibility toward subsequent infections with 
P. aeruginosa. Our data suggest that 
patients subjected to antimicrobial therapy 
might benefit from strategies to increase 
pulmonary IgA levels to decrease their risk 
of developing bacterial pneumonia.
Methods
Mice and antibiotic treatment. Female 
C57BL/6 WT mice or KO mice on the same 
background were used for the experiments. 
To virtually deplete the intestinal microbiota, 6- to 8-week-old mice 
were transferred to sterile cages and treated by adding ampicillin (1 g/l; 
Ratiopharm), vancomycin (500 mg/l; Cell Pharm), ciprofloxacin 
(200 mg/l; Bayer Vital), imipenem (250 mg/l; MSD), and metronida-
zole (1 g/l; Fresenius) to the drinking water ad libitum for 6–8 weeks 
as described before (ABx mice) (25). Antibiotic-treated animals were 
monitored for fungal outgrowth. Mice in which fungal outgrowth 
was observed were eliminated from the study. Other 8-week-old ani-
mals were treated by adding amoxicillin and clavulanic acid (1 g/l 
Amox/142.5 mg/l Clav; 1A Pharma) to the drinking water ad libitum 
(renewed every 2 days, AmoxClav mice). Control mice for the ABx or 
AmoxClav groups were maintained in the same facilities during the 
same period of time as the animals undergoing antibiotic treatment. 
IgA–/– (Laboratory Animals Services Center), Taci/Bcma–/– (provided 
by Susan Kalled, Biogen) (51), Tlr2/4–/–, 3d/Tlr2/4/5–/– (52), and Tcrbd–/– 
mice (provided by Max Löhning, Charité Universitätsmedizin Berlin) 
Table 1. Summary of patient cohorts
Patients without ABx Patients with ABx P
Age, y (range) 54.3 (23–71) 42.7 (22–68) 0.13
Female, % (n) 10 (1) 40 (4) 0.13
Weight, kg (range) 80.9 (61–100) 78.3 (65–92) 0.65
Height, cm (range) 173.7 (167–185) 173.3 (165–180) 0.89
BMI (range) 26.8 (18.4–31.6) 25.95 (22.5–28.7) 0.57
SOFA (range) 14.8 (9–24) 13.4 (10–22) 0.50
SAPSIII (range) 28.1 (12–39) 29.1 (18–37) 0.76
Days on ventilator before BAL (range) 1.2 (1–2) 1.8 (1–3) 0.077
CRP, mg/dl (range) 1.77 (0.7–3.7) 2.14 (1.0–3.4) 0.38
WBC, g/l (range) 8.8 (7.0–12.2) 9.4 (5.5–12.9) 0.50
AntibioticsA NA (PipT)Co-trim, Teic
NA (PipT, Co-trim) Mero, Teic
NA (PipT, Co-trim) Mero, Teic
NA (PipT, Clin) Mero, Teic
NA (PipT, Co-trim) Mero, Teic 
NA (Mero, Teic) Co-trim, Metro
NA (Mero, Teic, Cefta) Line
NA (CeftT, Clin, Co-amox) Mero, Teic
NA (PipT, Teic) Dapto, Imi
NA (Pen, PipT, Co-amox) Mero, Teic
Main diagnosis Cardiac arrest ARDS
Lung fibrosis Lung fibrosis
Trauma Influenza
Cardiac arrest Lung fibrosis
Cardiac arrest Influenza
Status epilepticus Influenza
Thymom ARDS
Cardiac arrest Pneumonia
Cardiac arrest ARDS
Status epilepticus Pneumonia
AAntibiotics in parentheses were given to the patient previously during the same hospital stay; 
antibiotics not in parentheses were given to the patient at the time of sampling. ABx, antibiotic; ARDS, 
acute respiratory distress syndrome; BMI, body mass index; Cefta, ceftazidime; CeftT, ceftolozane/
tazobactam; Clin, clindamycin; Co-amox, co-amoxiclav; Co-trim, co-trimoxazole; CRP, C-reactive protein; 
Dapto, daptomycin; Line, linezolid; Mero, meropenem; Metro, metronidazole; Pen, penicillin; PipT, 
piperacillin/tazobactam; SAPSIII, simplified acute physiology score III; SOFA, sepsis-related organ 
failure assessment score; Teic, teicoplanin; WBC, white blood count.
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GCAGCAG/TAMRA-3′) (56). Relative quantification was calculated 
by division with the control group.
Germ-free mice. GF C57BL/6 mice were bred and kept in the ani-
mal facilities at the University of Marburg. GF mice were kept in plas-
tic isolators (Metall and Plastik) with autoclaved food, bedding, and 
water. Sterility of animals was checked biweekly by culturing feces in 
thioglycollate medium under aerobic and anaerobic conditions for at 
least 10 days. All handling procedures for GF mice were conducted in 
a laminar flow hood under sterile conditions. All experiments were 
conducted according to German animal protection law.
Oral and intranasal LPS application in antibiotic-treated mice. Dur-
ing the antibiotic treatment, mice received LPS (from Escherichia coli 
O111:B4; Sigma, catalog L2630) orally by adding 15 μg/ml LPS (57) to 
the drinking water ad libitum during the last 3 weeks of the antibiotic 
treatment (day –27 until day –4 or day –6 before infection), or mice 
received 2 μg LPS intranasally 3 consecutive times (days –22, –13, and 
–5 before infection)(20).
Pseudomonas aeruginosa infection. P. aeruginosa strain PA103 was 
from ATCC (ATCC29260). PA103 was cultured in Luria Bertani (LB) 
or Tryptic Soy (TSB) broth to mid-logarithmic phase, washed twice in 
PBS, and inoculated into anesthetized mice (10 μl in each nostril) for 
an infection dose of 1 × 105 CFU per mouse. Control groups received 
PBS in an identical manner. At indicated time points, mice were sacri-
ficed, blood was drawn, and whole lungs were harvested and homog-
enized in sterile PBS. Bacterial loads were quantified in lung homog-
on C57BL/6 background were housed under specific pathogen-free 
conditions and comparatively analyzed with WT control animals that 
were housed in the same facilities.
Intestinal microbiota analyses. For molecular analysis of the intes-
tinal microbiota, DNA was extracted from fecal samples as previously 
described (25). Briefly, DNA extracts and plasmids were quantified 
using Quant-iT PicoGreen reagent (Invitrogen) and adjusted to 1 ng/
μl. Then, abundance of the main bacterial groups of murine intestinal 
microbiota was assessed by quantitative real-time PCR (qRT-PCR) 
with group-specific 16S rRNA gene primers (Tib MolBiol) as previ-
ously described (53, 54). The number of 16S rRNA gene copies per 
microgram DNA of each sample was determined and frequencies 
of respective bacterial groups were calculated proportionally to the 
eubacterial (V3) amplicon.
Respiratory tract microbiota analyses. The protocol was adapted 
from ref. 55. BALF and upper respiratory lavage (URL) samples from 
3 mice were pooled. After host cell removal by centrifugation, BAL or 
URL DNA was extracted by bead homogenization and isolated using 
the Qiagen DNeasy Blood & Tissue Kit. The control group (in triplicate) 
consisted of PBS that had been processed the same way as the BAL 
and URL samples. Total bacterial qPCR was performed using a 10:1 
mixture of the universal forward primers 8FM (5′-AGAGTTTGATC-
MTGGCTCAG-3′) and 8FB (5′-AGGGTTCGATTCTGGCTCAG-3′), 
with reverse primer Bact515R (5′-TTACCGCGGCKGCTGGCAC-3′) 
and TaqMan probe Bact338K (5′-FAM/CCAKACTCCTACGGGAG-
Figure 5. Local application of IgA enhances the antibacterial defense against P. aeruginosa in antibiotic-treated animals.  (A–D) IgA was purified from ex 
vivo murine lamina propria culture, and purified lamina propria IgA (IgALP) or PBS was intranasally applied to animals pretreated with antibiotic 30 minutes 
prior to infection with P. aeruginosa. Bacterial loads (n = 12 for mice with and without IgA treatment) in (A) lung and (B) blood, and (C) body temperature  
(n = 8 for mice with and without IgA treatment) were measured 24 hours after infection, or survival was monitored over 4 days (n = 17 for mice with and 
without IgA treatment) (D). (E) Pooled hybridoma IgA (IgAH) preparations were tested in vitro for their binding to P. aeruginosa. (F and G) High and non– 
P. aeruginosa–binding IgA prepared from IgA hybridoma were administrated intranasally 30 minutes prior to infection and P. aeruginosa loads were mea-
sured 24 hours later in lung (F) and blood (G) (n = 9 mice for PBS group, n = 12 mice for high P. aeruginosa–binding IgA, n = 10 mice for non–P. aeruginosa–
binding IgA). Values are mean ± SD, each dot corresponds to the data from one mouse. Mann-Whitney U tests were applied to the data set, except for 
survival and body temperature data. A t test with Welch’s correction was applied to body temperature data (see Methods). The Gehan-Breslow Wilcoxon 
test was applied to the survival data. *P < 0.05.
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IgA-producing plasma cells as B220lo, CD138hi, and IgAhi. Fluorescence 
minus one (FMO) was performed when necessary.
Purification of polyclonal murine IgA. Intestines from C57Bl/6 mice 
were extensively washed in PBS/BSA containing penicillin and strep-
tomycin and cultured in RPMI-1640 supplemented with 10% FCS/
penicillin/streptomycin at 37°C and 5% CO2 in tissue flask. Tissues 
were kept in cultures for 2 weeks with complete medium replacement 
every 2 days. Harvested culture supernatants were centrifuged, filtered 
via 0.2 μm filters, dialyzed in a total of 6 l PBS, and preserved at −20°C 
for further purification. IgA was purified using protein L-Sepharose, 
and IgA concentration and purity were determined by gel electropho-
resis and ELISA (amount of IgA was 50 μg/ml, whereas IgM and IgG 
levels were as low as 6 μg/ml or 1.2 μg/ml, respectively).
Generation of IgA hybridomas and purification of IgA. Lamina pro-
pria cells were isolated by digesting C57Bl/6 intestines using 1 mg/ml 
collagenase D (Roche Diagnostics) and 1 mg/ml dispase II (Sigma- 
Aldrich). Cells were further fused with P3X63Ag8.653 myeloma cells 
(ATCC) using 50% polyethylene glycol (Mr ~1450 Da) and were cul-
tured in RPMI-1640 containing 20% FBS, 1% penicillin and strep-
tomycin, 100 μM hypoxanthine, 0.4 μM aminopterin, and 16 μM 
thymidine. Cloned hybridomas were tested for IgA by ELISA and 
homogeneity of IgA expression was examined by flow cytometry. 
Monoclonal IgA antibodies were purified from supernatants using 
Sepharose conjugated with anti–IgA antibody (Southern Biotech).
IgA treatment of microbiota-depleted animals. Antibiotic-pretreated 
mice were anesthetized and purified IgA from lamina propria (1 μg per 
mouse) or hybridoma (1 μg per mouse) or PBS was given intranasally 
30 minutes prior to infection with P. aeruginosa.
Human samples. The patient cohorts were recruited from the ter-
tiary care ICU of a university clinic from 2016–17. Patients gave their 
informed consent for sampling. Inclusion criteria comprised endotra-
cheal intubation, 18 years and older, antibiotic therapy for at least 2 
weeks prior, or no antibiotic therapy for at least 3 months prior. Exclu-
sion criteria comprised active infection, pregnancy, and immunode-
ficiency. BALF was obtained by the same experienced physician to 
avoid interindividual variability. Patients received sedoanalgesia with 
propofol and/or midazolam by the physician in charge to minimize 
discomfort, as well as standard monitoring (ECG, heart rate, blood 
pressure, oximetry). After positioning the bronchoscope in a wedge 
position, 10 ml saline was instilled and extracted by suction. Samples 
were centrifuged (4,000 g for 10 minutes), supernatants were aliquot-
ed in sterile tubes, and kept frozen at –80°C until further use.
Statistics. Data are mean ± SD. For comparison of 2 groups, the 
Mann-Whitney U test (2-tailed) was used. When the normality test 
(D’Agostino & Pearson omnibus normality test) was passed, paramet-
ric statistical analyses were applied: unpaired t test with Welch’s cor-
rection (2-tailed). For all statistical analyses, P < 0.05 was considered 
significant with *P < 0.05, **P < 0.01, ***P < 0.005. To detect a pos-
sible influence of APRIL and BAFF on IgA levels in patients, univariate 
analysis was used.
Study approval. All animal experiments were carried out in strict 
adherence to the Animal Protection Act under German law, follow-
ing the approval of the corresponding institutional (Charité-Univer-
sitätsmedizin Berlin) and governmental (LAGeSo Berlin, approval 
ID G0367/11, G0178/14, and G0100/16) animal welfare authorities. 
The human part of the trial was approved by the institutional review 
board (Ethics Committee of the Medical University of Vienna, identi-
enates, BALs, and blood by serial dilutions and plating on agar plates. 
The remaining lung homogenates were spun down (300 g for 15 min-
utes) to separate cells (for further FACS analysis or RNA extraction) 
from supernatants (for ELISA). BAL was performed 6 and 12 hours 
after infection for cell recruitment analysis by FACS and ELISA.
ELISAs. Levels of prostaglandin E2 (PGE2) and the following 
cytokines and immunoglobulins were measured by ELISAs accord-
ing to the manufacturers’ recommendations: mPGE2 (R&D Systems, 
catalog KGE004B), mIL-1α (eBioscience, catalog 50-112-5107), mIL-
1β (eBioscience, catalog 88-7013-88), mTNF-α (eBioscience, catalog 
88-7324-88), mIL-6 (eBioscience, catalog 88-7064-88), mCXCL1 
(R&D Systems, catalog DY453-05), mCXCL2 (R&D Systems, catalog 
DY452-05), CCL2 (eBioscience, catalog 88-7391-22), mBAFF (R&D 
Systems, catalog MBLYS0), mAPRIL (LSBio, catalog LS-F7691), mIgM 
(eBioscience, catalog 88-50470-22), mIgG (eBioscience, catalog 
88-50400), mIgA (eBioscience, catalog 88-50450-77, or direct ELISA 
with anti–mouse IgA/HRP cross-adsorbed from Thermo Fisher Sci-
entific, catalog PA1-74397), hIgA (Thermo Fisher Scientific, catalog 
88-50600-77), hIgM (eBioscience, catalog 88-50620-22), and hIgG 
(Thermo Fisher Scientific, catalog BMS2091TEN). For the IgA-binding 
ELISA, a mid-logarithmic phase PA103 suspension was washed twice 
with PBS and adjusted to an OD of 0.2, and then transferred onto a 
96-well plate, spun-down (500 g for 10 minutes), and dried out after 
supernatant removal. After blocking, BAL samples were loaded onto 
the plate and incubated for 2 hours at room temperature. Binding IgA 
ELISAs and direct IgA ELISAs were detected by anti–mouse IgA/HRP 
(Thermo Fisher Scientific, catalog PA1-74397). Lung permeability was 
determined by quantifying Evans blue dye leakage into the lung.
qPCR. RNA was extracted by Trizol from whole-lung homog-
enates. After reverse transcription using the High Capacity Reverse 
Transcription Kit (Applied Biosystems), targeted cDNA was amplified 
and measured by Taqman assay on an AB Applied Biosystems thermo-
cycler. Primers used were IL-10 (Mm00439614, Thermo Fisher Sci-
entific) and GAPDH (fwd: 5′-TGTGTCCGTCGTGGATCTGA-3′, rev: 
5′-CCTGCTTCACCACCTTCTTGA-3′, probe: 5′-FAM-CCGCCTG-
GAGAAACCTGCCAAGTATG–TAMRA-3′). Relative quantification 
(RQ) values were calculated based on ΔΔCt, with conventionally colo-
nized PBS-treated mice as a control group.
Flow cytometry analysis. For recruited neutrophils and macrophages, 
cells from BAL were gathered by spinning down the BALF (400 g for 10 
minutes RT). After incubation with blocking antibody (anti-CD16/32, 
BioLegend, catalog 101302), cells were stained using CD11c-FITC 
(N418, BioLegend), SiglecF-PE (E50-2440, BD Biosciences), F4/80-
APC (BM8, BioLegend), CD45-Alexa700 (30-F11, BioLegend), Ly6G-
BV421 (1A8, BioLegend), and CD11b-BV510 (M1/70, BioLegend). 
Beads for counting were used as recommended by the manufacturer 
(CountBright beads, Molecular Probes). For IgA-producing plasma cells, 
the lungs were mashed through a 100-μm filter. After incubation with 
blocking antibody (anti-CD16/32, BioLegend), cells were stained using 
IgA-FITC (mA-6E1, eBioscience, intracellular staining), B220-Alexa700 
(RA3-6B2, BioLegend), and CD138-BV421 (281-2, BioLegend). Intra-
cellular staining using BD Cytofix/Cytoperm solution (Thermo Fisher 
Scientific) was done according to the manufacturer’s recommendations. 
The samples were acquired on FACS CantoII (Becton Dickinson). Data 
were analyzed using the FlowJo data analysis software. Gating strategies 
were processed after exclusion of the doublets. Alveolar macrophages 
were defined as CD11c+ SiglecF+, neutrophils as CD11b+ Ly6G+, and 
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